Wave Life Sciences, Inc. (WVE) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN USY953081053
Wave Life Sciences, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 42.73 m USD |
| Operating income | -215.38 m USD |
| EBIT | -214.86 m USD |
| Net income | -204.38 m USD |
| Diluted EPS – continuing operations | -1.21 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Wave Life Sciences, Inc.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
More stocks
- Beijing Deep Glint Technology Co. Ltd. A (688207.SS)
- LINCOLN EDUCATIONAL SERVICES CORP (LINC)
- ASOS PLC (ASC.L)
- Red Cat Holdings, Inc. (RCAT)
- STRATUS (5356.KL)
- Phoenix Education Partners, Inc. (PXED)
- ACNB CORP (ACNB)
- Ginkgo Bioworks Holdings, Inc. (DNA)
- Yixin Group Ltd (2858.HK)
- Ascopiave SpA (ASC.MI)
- New East New Materials Co Ltd (603110.SS)
- CTT Correios de Portugal SA (CTT.LS)
Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.